Assurance de qualité pour le cancer rectal – phase 2 ...

More documents

Recommendations

Info

96 PROCARE – phase 2 KCE reports 81Quality indicator Subdiscipline(s) Source Ex/inclusion Level Final QI(s)IF a patient has a malignant rectal tumour excised, THEN a medical recordshould state the distance from the anal vergeIF a patient has surgical excision of a malignant colorectal tumour, THENthe patient should have colonoscopy or barium enema to assess for thepresence of synchronous tumours or polyps between 6 months beforeand 16 weeks after the surgical excisionIF a patient has a malignant rectal tumour and undergoes transrectalultrasound, THEN the transrectal ultrasound should occur beforeradiotherapyIF a patient has a stage II or III rectal cancer and received chemotherapy,THEN the patient should start chemotherapy within 8 weeks of firstpositive biopsy OR within 8 weeks of surgical resectionIF a patient has a malignant tumour of the colon or rectum excised, THENthe pathology report should state whether or not the tumour involveslymph nodesIF a patient has a malignant tumour of the colon or rectum excised, THENthere should be evidence that a lymphadenectomy was performedIF a patient has primary rectal cancer and does not have a T4 tumour ORa documented intraoperative complication that led to prematuretermination of the operation, THEN the surgical pathology report shoulddocument that the radial margin of the surgical specimen is free of tumourIF the patient receives a diverting ileostomy or colostomy, THEN thepatient should receive enterostomy care and management instructionsbefore discharge or receive a home healthcare follow-upIF a patient has a malignant rectal tumour and undergoes transrectalultrasound, THEN the ultrasound report should state the depth ofinvasion of the tumourIF a patient has malignant tumour of the colon or rectal cancer andhas the malignant tumour excised and is seen in consultation by amedical oncologist, THEN the medical oncologist's medical recordsshould document at least one of the following:1. AJCC stage or TNM stage OR2. Nodal status and, if lymph nodes negative, the depth ofinvasionStaging NICCQ Inclusion 2 1211Staging NICCQ Inclusion 2 1214Staging NICCQ Inclusion 2 1215Adjuvant NICCQ Inclusion 2 1243Pathology NICCQ Inclusion 2 1274NICCQ Exclusion 3NICCQ Exclusion 3NICCQ Exclusion 3NICCQ Exclusion 3NICCQ Exclusion 3
KCE Reports 81 PROCARE – phase 2 97Quality indicator Subdiscipline(s) Source Ex/inclusion Level Final QI(s)IF a patient has a malignant tumour of the colon or rectumNICCQ Exclusion 3surgically excised and is seen in consultation by a radiationoncologist, THEN the radiation oncologist's medical record shoulddocument at least one of the following:1. AJCC stage or TNM stage OR2. Nodal status and, if lymph nodes negative, the depth ofinvasion size and lymph node statusIF a patient is treated with chemotherapy, THEN the planned doseNICCQ Exclusion 3(dose per cycle x number of cycles) should be documented in themedical oncology or integrated recordIF a patient is treated with chemotherapy, THEN the planned doseNICCQ Exclusion 3(dose per cycle x number of cycles) should fall within a range thatis consistent with published regimensIF a patient is treated with chemotherapy, THEN body-surface areaNICCQ Exclusion 3should be documentedIF a patient has a malignant tumour of the colon or rectum excised,NICCQ Exclusion 3THEN the pathology report should state the depth of invasion ofthe tumourIF a patient has a malignant rectal tumour excised, THEN theNICCQ Exclusion 3pathology report should state the presence or absence oflymphovascular invasionIF a patient has a malignant rectal tumour excised, THEN theNICCQ Exclusion 3pathology report should comment on the presence or absence ofmicroscopic tumour cells at the resection marginIF a patient has resection of a malignant tumour of the colon (butNICCQ Not rectalnot rectum) and not a T4 lesion OR a documented intraoperativecomplication that led to premature termination of the operation,THEN the last pathology report associated with the resectionshould note that the margins of the operative specimen should befree of tumourIF a patient has stage II colon cancer features that increase the riskof recurrence (obstruction, perforation, or T4 lesions) or stage IIIcolon cancer, THEN the patient should receive adjuvantchemotherapy with a regimen listed in Table A or was in a clinicaltrialNICCQ Not rectal
Page 1 and 2:
Assurance de qualitépour le cancer
Page 3 and 4:
Assurance de qualité pour lecancer
Page 5 and 6:
KCE Reports 81B Cancer rectal - pha
Page 7:
KCE Reports 81B Cancer rectal - pha
Page 10 and 11:
vi Cancer rectal - phase 2 KCE Repo
Page 12 and 13:
2 PROCARE - phase 2 KCE reports 81A
Page 14 and 15:
4 PROCARE - phase 2 KCE reports 811
Page 16 and 17:
6 PROCARE - phase 2 KCE reports 81F
Page 19 and 20:
KCE Reports 81 PROCARE - phase 2 92
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56: KCE Reports 81 PROCARE - phase 2 45
Page 87 and 88: KCE Reports 81 PROCARE - Phase 2 77
Page 105: KCE Reports 81 PROCARE - phase 2 95
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169:
Page 172 and 173:
Dépôt légal : D/2008/10.273/39
Page 174 and 175:
35. Etude relative aux coûts poten
show all

Assurance de qualité pour le cancer rectal – phase 2 ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?